Travel Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Composition (Mono Vaccines v/s Combination Vaccines), By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others), By Travel Type (Domestic v/s International) By Region & Competition, 2021-2031F
The Global Travel Vaccine Market is projected to expand from USD 6.81 Billion in 2025 to USD 11.56 Billion by 2031, achieving a CAGR of 9.22%. Travel vaccines are biological preparations designed to provide acquired immunity against endemic infectious diseases for individuals traveling to specific regions. The market's growth is primarily fueled by the strong recovery of international tourism and stringent government mandates that require immunization for visa approvals. This expansion is further bolstered by rising global disposable incomes, which enable greater cross-border mobility and business travel. UN Tourism data indicates that in 2024, international tourist arrivals recovered to 96 percent of pre-pandemic levels within the first seven months, signaling a robust resurgence in global movement that directly drives the demand for prophylactic healthcare measures.
Despite these favorable growth indicators, the market encounters significant obstacles related to the complex logistics required for vaccine distribution. Stringent cold chain storage necessities impose high operational costs and create distribution inefficiencies, particularly in developing nations that lack robust infrastructure. Consequently, these supply chain constraints constitute a substantial challenge that could limit the widespread accessibility of essential immunizations and hinder the overall expansion of the global travel vaccine sector.
Market Driver
The revival of global international tourism and business travel serves as a major catalyst for market expansion, as heightened mobility directly leads to increased vaccine administration. As air connectivity improves and borders fully reopen, travelers are increasingly visiting exotic and tropical locations where endemic diseases present significant health risks, necessitating prophylactic immunization. This upward trend in mobility secures a sustained patient base for travel medicine clinics and pharmaceutical manufacturers, particularly for vaccines protecting against hepatitis A, typhoid, and yellow fever. Highlighting this recovery, the International Air Transport Association's 'Air Passenger Market Analysis' from July 2024 noted that total international passenger demand increased by 14.6 percent in May 2024 compared to the previous year, underscoring the rapid restoration of cross-border movement that supports market demand.
Simultaneously, the rising prevalence of emerging and re-emerging infectious diseases in popular tourist destinations compels travelers to obtain vaccinations before departure. Outbreaks of vector-borne illnesses in tropical regions have increased the urgency for preventative measures among tourists and business expatriates, driving the adoption of newly approved immunization options. For example, the significant expansion of dengue fever transmission zones has created an acute demand for preventative solutions. The Pan American Health Organization reported in its March 2024 'Epidemiological Update Dengue' that the Americas region saw over 3.5 million suspected dengue cases in early 2024, a staggering rise compared to historical averages. This epidemiological landscape generates tangible financial gains for vaccine developers; Bavarian Nordic reported that its Travel Health segment achieved revenues of DKK 1,877 million for the full year of 2023, reflecting the robust commercial impact of high infection risks.
Market Challenge
Complex logistics and stringent cold chain storage requirements act as a formidable barrier to the growth of the Global Travel Vaccine Market. Travel vaccines are biological products that typically require precise temperature controls, ranging from refrigerated to cryogenic states, throughout their entire transit. in regions with underdeveloped infrastructure, maintaining this thermal continuity is both operationally difficult and financially burdensome. The resulting high operational costs and elevated risks of product spoilage deter manufacturers and distributors from efficiently expanding into these markets. Consequently, this logistical fragility effectively places a ceiling on revenue potential, as the industry struggles to guarantee the reliable availability of essential immunizations in destinations where they are most needed.
This operational strain is further intensified by the immense volume of products that must navigate these often-constrained supply networks. The pressure to transport vast quantities of temperature-sensitive vials amplifies existing distribution inefficiencies. According to UNICEF's Supply Annual Report 2024, the organization managed the international delivery of 2.787 billion vaccine doses to 99 countries in 2024. Processing such a massive volume through fragile cold chains inevitably leads to bottlenecks and supply interruptions. These constraints directly restrict market reach and undermine the industry's capacity to fully capitalize on the heightened demand for prophylactic healthcare driven by the resurgence of global tourism.
Market Trends
The commercialization of novel vaccines for vector-borne diseases is shifting the market from research to the availability of approved prophylactics for neglected tropical illnesses. Developers are navigating regulatory pathways to launch immunizations for diseases like chikungunya, filling the preventative care gap for travelers visiting endemic regions. This transition from pipeline to product generates immediate commercial value and expands the travel health portfolio beyond traditional vaccines. According to Bavarian Nordic A/S, in its November 2025 'Interim Results for the First Nine Months of 2025', Travel Health revenue increased by 23 percent to DKK 2,327 million, a growth trajectory supported by the commercial launch of its chikungunya vaccine, Vimkunya.
Concurrently, the development of multivalent and combination vaccine formulations is reshaping immunization strategies by offering broad-spectrum protection through single-product solutions. Manufacturers are prioritizing tetravalent technologies that induce immunity against multiple virus serotypes simultaneously, simplifying vaccination schedules and enhancing traveler compliance compared to monovalent alternatives. This innovation improves clinical outcomes and drives market uptake by streamlining the logistical burden for travel medicine providers. According to Takeda Pharmaceutical Company Limited's January 2025 'earnings results for the third quarter of fiscal year 2024', the company reported that its tetravalent dengue vaccine, Qdenga, generated 19.9 billion JPY in revenue for the first half of the fiscal year, marking an 863 percent increase.
Key Market Players
In this report, the Global Travel Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Travel Vaccine Market.
Available Customizations:
Global Travel Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these favorable growth indicators, the market encounters significant obstacles related to the complex logistics required for vaccine distribution. Stringent cold chain storage necessities impose high operational costs and create distribution inefficiencies, particularly in developing nations that lack robust infrastructure. Consequently, these supply chain constraints constitute a substantial challenge that could limit the widespread accessibility of essential immunizations and hinder the overall expansion of the global travel vaccine sector.
Market Driver
The revival of global international tourism and business travel serves as a major catalyst for market expansion, as heightened mobility directly leads to increased vaccine administration. As air connectivity improves and borders fully reopen, travelers are increasingly visiting exotic and tropical locations where endemic diseases present significant health risks, necessitating prophylactic immunization. This upward trend in mobility secures a sustained patient base for travel medicine clinics and pharmaceutical manufacturers, particularly for vaccines protecting against hepatitis A, typhoid, and yellow fever. Highlighting this recovery, the International Air Transport Association's 'Air Passenger Market Analysis' from July 2024 noted that total international passenger demand increased by 14.6 percent in May 2024 compared to the previous year, underscoring the rapid restoration of cross-border movement that supports market demand.
Simultaneously, the rising prevalence of emerging and re-emerging infectious diseases in popular tourist destinations compels travelers to obtain vaccinations before departure. Outbreaks of vector-borne illnesses in tropical regions have increased the urgency for preventative measures among tourists and business expatriates, driving the adoption of newly approved immunization options. For example, the significant expansion of dengue fever transmission zones has created an acute demand for preventative solutions. The Pan American Health Organization reported in its March 2024 'Epidemiological Update Dengue' that the Americas region saw over 3.5 million suspected dengue cases in early 2024, a staggering rise compared to historical averages. This epidemiological landscape generates tangible financial gains for vaccine developers; Bavarian Nordic reported that its Travel Health segment achieved revenues of DKK 1,877 million for the full year of 2023, reflecting the robust commercial impact of high infection risks.
Market Challenge
Complex logistics and stringent cold chain storage requirements act as a formidable barrier to the growth of the Global Travel Vaccine Market. Travel vaccines are biological products that typically require precise temperature controls, ranging from refrigerated to cryogenic states, throughout their entire transit. in regions with underdeveloped infrastructure, maintaining this thermal continuity is both operationally difficult and financially burdensome. The resulting high operational costs and elevated risks of product spoilage deter manufacturers and distributors from efficiently expanding into these markets. Consequently, this logistical fragility effectively places a ceiling on revenue potential, as the industry struggles to guarantee the reliable availability of essential immunizations in destinations where they are most needed.
This operational strain is further intensified by the immense volume of products that must navigate these often-constrained supply networks. The pressure to transport vast quantities of temperature-sensitive vials amplifies existing distribution inefficiencies. According to UNICEF's Supply Annual Report 2024, the organization managed the international delivery of 2.787 billion vaccine doses to 99 countries in 2024. Processing such a massive volume through fragile cold chains inevitably leads to bottlenecks and supply interruptions. These constraints directly restrict market reach and undermine the industry's capacity to fully capitalize on the heightened demand for prophylactic healthcare driven by the resurgence of global tourism.
Market Trends
The commercialization of novel vaccines for vector-borne diseases is shifting the market from research to the availability of approved prophylactics for neglected tropical illnesses. Developers are navigating regulatory pathways to launch immunizations for diseases like chikungunya, filling the preventative care gap for travelers visiting endemic regions. This transition from pipeline to product generates immediate commercial value and expands the travel health portfolio beyond traditional vaccines. According to Bavarian Nordic A/S, in its November 2025 'Interim Results for the First Nine Months of 2025', Travel Health revenue increased by 23 percent to DKK 2,327 million, a growth trajectory supported by the commercial launch of its chikungunya vaccine, Vimkunya.
Concurrently, the development of multivalent and combination vaccine formulations is reshaping immunization strategies by offering broad-spectrum protection through single-product solutions. Manufacturers are prioritizing tetravalent technologies that induce immunity against multiple virus serotypes simultaneously, simplifying vaccination schedules and enhancing traveler compliance compared to monovalent alternatives. This innovation improves clinical outcomes and drives market uptake by streamlining the logistical burden for travel medicine providers. According to Takeda Pharmaceutical Company Limited's January 2025 'earnings results for the third quarter of fiscal year 2024', the company reported that its tetravalent dengue vaccine, Qdenga, generated 19.9 billion JPY in revenue for the first half of the fiscal year, marking an 863 percent increase.
Key Market Players
- GlaxoSmithKline, plc
- Sanofi S.A.
- Novartis International AG
- Merck KGaA
- Pfizer Inc.
- AstraZeneca Plc
- Abbott Laboratories, Inc
- F. Hoffmann-La Roche AG
- CSL Limited
- Johnson & Johnson
In this report, the Global Travel Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Travel Vaccine Market, By Composition
- Mono Vaccines v/s Combination Vaccines
- Travel Vaccine Market, By Disease Indication
- Hepatitis A
- DPT
- Yellow Fever
- Typhoid
- Hepatitis B
- Measles and Mumps
- Rabies
- Meningococcal
- Varicella
- Japanese Encephalitis
- Others
- Travel Vaccine Market, By Travel Type
- Domestic v/s International
- Travel Vaccine Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Travel Vaccine Market.
Available Customizations:
Global Travel Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL TRAVEL VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Composition (Mono Vaccines v/s Combination Vaccines)
5.2.2. By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others)
5.2.3. By Travel Type (Domestic v/s International)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA TRAVEL VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Composition
6.2.2. By Disease Indication
6.2.3. By Travel Type
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Travel Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Composition
6.3.1.2.2. By Disease Indication
6.3.1.2.3. By Travel Type
6.3.2. Canada Travel Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Composition
6.3.2.2.2. By Disease Indication
6.3.2.2.3. By Travel Type
6.3.3. Mexico Travel Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Composition
6.3.3.2.2. By Disease Indication
6.3.3.2.3. By Travel Type
7. EUROPE TRAVEL VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Composition
7.2.2. By Disease Indication
7.2.3. By Travel Type
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Travel Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Composition
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By Travel Type
7.3.2. France Travel Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Composition
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By Travel Type
7.3.3. United Kingdom Travel Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Composition
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By Travel Type
7.3.4. Italy Travel Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Composition
7.3.4.2.2. By Disease Indication
7.3.4.2.3. By Travel Type
7.3.5. Spain Travel Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Composition
7.3.5.2.2. By Disease Indication
7.3.5.2.3. By Travel Type
8. ASIA PACIFIC TRAVEL VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Composition
8.2.2. By Disease Indication
8.2.3. By Travel Type
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Travel Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Composition
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By Travel Type
8.3.2. India Travel Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Composition
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By Travel Type
8.3.3. Japan Travel Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Composition
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By Travel Type
8.3.4. South Korea Travel Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Composition
8.3.4.2.2. By Disease Indication
8.3.4.2.3. By Travel Type
8.3.5. Australia Travel Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Composition
8.3.5.2.2. By Disease Indication
8.3.5.2.3. By Travel Type
9. MIDDLE EAST & AFRICA TRAVEL VACCINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Composition
9.2.2. By Disease Indication
9.2.3. By Travel Type
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Travel Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Composition
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Travel Type
9.3.2. UAE Travel Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Composition
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Travel Type
9.3.3. South Africa Travel Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Composition
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Travel Type
10. SOUTH AMERICA TRAVEL VACCINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Composition
10.2.2. By Disease Indication
10.2.3. By Travel Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Travel Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Composition
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Travel Type
10.3.2. Colombia Travel Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Composition
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Travel Type
10.3.3. Argentina Travel Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Composition
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Travel Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL TRAVEL VACCINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. GlaxoSmithKline, plc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sanofi S.A.
15.3. Novartis International AG
15.4. Merck KGaA
15.5. Pfizer Inc.
15.6. AstraZeneca Plc
15.7. Abbott Laboratories, Inc
15.8. F. Hoffmann-La Roche AG
15.9. CSL Limited
15.10. Johnson & Johnson
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL TRAVEL VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Composition (Mono Vaccines v/s Combination Vaccines)
5.2.2. By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others)
5.2.3. By Travel Type (Domestic v/s International)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA TRAVEL VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Composition
6.2.2. By Disease Indication
6.2.3. By Travel Type
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Travel Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Composition
6.3.1.2.2. By Disease Indication
6.3.1.2.3. By Travel Type
6.3.2. Canada Travel Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Composition
6.3.2.2.2. By Disease Indication
6.3.2.2.3. By Travel Type
6.3.3. Mexico Travel Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Composition
6.3.3.2.2. By Disease Indication
6.3.3.2.3. By Travel Type
7. EUROPE TRAVEL VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Composition
7.2.2. By Disease Indication
7.2.3. By Travel Type
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Travel Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Composition
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By Travel Type
7.3.2. France Travel Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Composition
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By Travel Type
7.3.3. United Kingdom Travel Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Composition
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By Travel Type
7.3.4. Italy Travel Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Composition
7.3.4.2.2. By Disease Indication
7.3.4.2.3. By Travel Type
7.3.5. Spain Travel Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Composition
7.3.5.2.2. By Disease Indication
7.3.5.2.3. By Travel Type
8. ASIA PACIFIC TRAVEL VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Composition
8.2.2. By Disease Indication
8.2.3. By Travel Type
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Travel Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Composition
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By Travel Type
8.3.2. India Travel Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Composition
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By Travel Type
8.3.3. Japan Travel Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Composition
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By Travel Type
8.3.4. South Korea Travel Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Composition
8.3.4.2.2. By Disease Indication
8.3.4.2.3. By Travel Type
8.3.5. Australia Travel Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Composition
8.3.5.2.2. By Disease Indication
8.3.5.2.3. By Travel Type
9. MIDDLE EAST & AFRICA TRAVEL VACCINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Composition
9.2.2. By Disease Indication
9.2.3. By Travel Type
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Travel Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Composition
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Travel Type
9.3.2. UAE Travel Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Composition
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Travel Type
9.3.3. South Africa Travel Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Composition
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Travel Type
10. SOUTH AMERICA TRAVEL VACCINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Composition
10.2.2. By Disease Indication
10.2.3. By Travel Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Travel Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Composition
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Travel Type
10.3.2. Colombia Travel Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Composition
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Travel Type
10.3.3. Argentina Travel Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Composition
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Travel Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL TRAVEL VACCINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. GlaxoSmithKline, plc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sanofi S.A.
15.3. Novartis International AG
15.4. Merck KGaA
15.5. Pfizer Inc.
15.6. AstraZeneca Plc
15.7. Abbott Laboratories, Inc
15.8. F. Hoffmann-La Roche AG
15.9. CSL Limited
15.10. Johnson & Johnson
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
